Predict your next investment

Private Equity
FINANCE | Investment Firms & Funds
omnescapital.com

See what CB Insights has to offer

Investments

316

Portfolio Exits

101

Funds

52

Partners & Customers

1

About Omnes Capital

Omnes Capital, fka Credit Agricole Private Equity, is a major private equity and infrastructure investment player. With €2.1 billion under management, Omnes Capital provides businesses with the equity they need to develop in its key areas of expertise: growth capital and buyouts, venture capital, renewable energies, co-investment, and secondary funds-of-funds. Omnes Capital was a subsidiary of Credit Agricole S.A. until March 2012. The company is now owned by its employees.

Omnes Capital Headquarter Location

37 - 41 rue du Rocher

Paris, 75008,

France

+33 (0)1 80 48 79 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Omnes Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Omnes Capital in 1 Expert Collection, including The Edge Computing Landscape.

T

The Edge Computing Landscape

113 items

Edge computing companies facilitate workload deployment in addition to providing data processing and storage at the farthest reaches of the network. These edge computing companies range from data centers at the edge to workload management tools designed to orchestrate edge deploy

Omnes Capital Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Omnes Capital Rank

Latest Omnes Capital News

Domain Therapeutics SA secures €39M Series A

May 10, 2022

Domain Therapeutics SA secures €39M Series A CPE News (5.10.2022) – Domain Therapeutics SA has raised €39 million in Series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and with participation of adMare BioInnovations, Schroder Adveq, Omnes Capital, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners. Strasbourg, France based Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. The company focuses on developing high-value drug candidates to tackle GPCR-mediated immunosuppression in immune-oncology. Domain Therapeutics has its Canadian office in Montreal. photo credit: Domain Therapeutics News Release adMare BioInnovations joins a $42m Series A financing in Domain TherapeuticsBird & Bird (Paris, France): Emmanuelle Porte (Partner) and Claire Tanguy (Associate) Advisors of investors : Jones Day: Geoffroy Pineau-Valencienne (Partner) and Jeanne Plé (Associate) Chammas Marcheteau (Paris, France): Jerôme Chapron (Partner), Pauline Vigneron (Associate) Taylor Wessing (Paris, France): Nicolas De Witt (Partner) McDermott Will & Emery (Paris, France): Emmanuelle Trombe (Partner), Laetitia de Dinechin (Associate) Intellectual Property : Lavery Avocats (Montreal, Canada): Alain Dumont (Partner) Advisors of investors : Financial advisors CenPonts Healthcare (Paris, France): Xianding Ma (Partner), Jinlong Yue (Executive Director) Contact Domain Therapeutics : Juliette Milleret – jmilleret@newcap.fr – +33 (6) 62 41 47 42 About Domain Therapeutics Domain Therapeutics, a biopharmaceutical company operating in France and Canada, is dedicated to the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. The company focuses on developing high-value drug candidates to tackle GPCR-mediated immunosuppression in immune-oncology. www.domaintherapeutics.com About Panacea Venture Panacea Venture is a healthcare focused venture capital firm, with offices in Shanghai, Hong Kong, and Silicon Valley. Founded in 2017, Panacea Venture focuses on investing in and incubating early-stage life science companies with breakthrough technologies and discoveries that can potentially address unmet medical needs and enhance the quality of life on a global scale.www.panaceaventure.com About CTI Life Sciences Based in Montreal, CTI Life Sciences Fund L.P. was created in 2006. The firm makes venture capital investments mostly in innovative high-quality biotech companies at the pre-clinical and clinical development stages, in North America, and primarily in Canada. With the recent first close of its third mandate, CTI Life Sciences Fund manages $345 million of assets. www.ctisciences.com About 3B Future Health Fund 3B Future Health Fund II S.C.A. SICAV-RAIF is a Luxembourg based investment fund with focus on early-stage investment opportunities in Europe and the U.S in areas of high unmet patient need, mainly oncology and rare disease therapeutics. The Fund is the second investment fund sponsored by Riccardo Braglia, Group Vice-Chairman and Board Member of 3B Future Holding SA, Switzerland (formerly Helsinn Holding Group) and Chairman and General Partner of 3B Future Health Fund I and II, Luxembourg. www.3bfuturehealth.com About adMare BioInnovations With a wealth of scientific discovery, Canada is primed to be a global leader in life sciences. To realize this potential, adMare uses its scientific and commercial expertise, specialized R&D infrastructure, and investment capital to build investable companies, robust ecosystems and industry-ready talent – and re-invests its returns back into the Canadian industry to ensure it is sustained for the long-term. www.admarebio.com About Schroder Adveq Schroders Capital is a leading global private markets investor and part of Schroders Group. With over USD 70 billion assets under management, the firm manages a range of investment strategies, including private equity, private debt, real estate, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing on behalf of institutions, consultants, family offices and individual investors. Schroders Capital operates out of 19 offices globally and employs over 500 professionals, combining global market coverage with local, on-the-ground presence. The private equity team of Schroders Capital provides its clients access to a broad range of private equity opportunities through direct, co-investment, secondaries and primary investments across buyout, growth and venture capital with a focus on fundamental value generation through transformational change. Sustainability is an integrated part of the firm’s investment process and Schroders Capital is rated A+ by the UNPRI. www.schroderscapital.com About Omnes Capital Omnes is a leading private equity and infrastructure investor. With over €5 billion in assets under management, it provides companies with the capital they need to fund their growth, in three key areas: venture capital, growth & buyout capital and infrastructure. Omnes is whollyowned by its employees. It is committed to ESG factors and has founded the Fondation Omnes to fund initiatives in favour of children and young people. It is a signatory to the United Nations Principles for Responsible Investment (PRI). www.omnescapital.com About Turenne Capital Created in May 2014, Sham Innovation Santé is an investment structure specializing in health innovation capital and is controlled and owned by Sham, a mutual insurance company specializing in the risk management of health, social and medical players. Sham is the leading French player in medical civil liability. Advised by Turenne Santé (Health Center of Turenne Group), Sham Innovation Santé’s mission is to support the growth and development phases of innovative companies in the health sector. Turenne Group, one of France’s leading private equity firms, has been helping entrepreneurs for 20 years with their projects for innovation, development, and the transmission of their companies. As an independent player, the group manages €1,4 billion in assets. Its teams of 70 professionals, including 56 investors, based in Paris, Lille, Lyon, Bordeaux, Marseille, Nice and Metz, support 200 business leaders in the sectors of healthcare, hotels, new technologies, distribution and innovative services. With more than €300m, our healthcare team (Turenne Santé) invests across the entire value creation chain for healthcare companies through various investment approaches. www.sham.fr / www.turennecapital.com About Theodorus Theodorus Funds are venture capital funds dedicated to early-stage tech investments. It invests mostly in Biotech, MedTech & AI companies with proprietary technologies. Besides its financing role, Theodorus also plays an active role in the development of its portfolio companies, guiding the company towards its success. Today, Theodorus holds 70M€ of assets under management, which helped fund >40 companies and create >700 M€ in value. Theodorus has offices in Montreal and Brussels. www.theodorus.be About Seventure Partners Seventure Partners is a long-term equity investor that actively supports innovative companies aiming at generating positive impact on humankind, society, sustainability and the planet. With €900m net commitments as of end 2021, Seventure is a leading venture capital firm in Europe backing high growth potential companies since 1997 in 2 main areas: 1) Life Sciences: biotech, health & digital Health, nutrition, foodtech, blue economy, aquaculture, animal & agriculture, sport & wellness with a specific interest for microbiome-related innovations across Europe, Israel, Asia and North America; 2) Digital Technologies in Western Europe. Seventure promotes the development of companies from inception (seed, venture) to later stage (growth, crossover, IPO) with deployed capital ranging from €500k to €10m per round and up to €20m per company. With Health for Life Capital™ funds (€160m and €250m commitments respectively in 2 vehicles) and its co-investment funds, Seventure is a worldwide leader in microbiome investments with more than 20 microbiome companies in its portfolio to date. www.seventure.fr Related

Omnes Capital Investments

316 Investments

Omnes Capital has made 316 investments. Their latest investment was in Qubit Pharmaceuticals as part of their Seed VC on June 6, 2022.

CBI Logo

Omnes Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/10/2022

Seed VC

Qubit Pharmaceuticals

$16.94M

Yes

3

5/12/2022

Series B

Therapixel

$15.63M

No

2

5/10/2022

Series A - II

Domain Therapeutics

$42M

Yes

4

4/19/2022

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

1/24/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/10/2022

5/12/2022

5/10/2022

4/19/2022

1/24/2022

Round

Seed VC

Series B

Series A - II

Unattributed

Series A

Company

Qubit Pharmaceuticals

Therapixel

Domain Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$16.94M

$15.63M

$42M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

2

4

10

10

Omnes Capital Portfolio Exits

101 Portfolio Exits

Omnes Capital has 101 portfolio exits. Their latest portfolio exit was Dispam on June 09, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/9/2022

Acq - Fin

1

2/22/2022

Acquired

1

11/3/2021

Merger

1

9/29/2021

IPO

Subscribe to see more

Subscribe to see more

10

6/29/2021

Acquired

Subscribe to see more

Subscribe to see more

10

Date

6/9/2022

2/22/2022

11/3/2021

9/29/2021

6/29/2021

Exit

Acq - Fin

Acquired

Merger

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Omnes Capital Acquisitions

63 Acquisitions

Omnes Capital acquired 63 companies. Their latest acquisition was Prima Vital on July 08, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/8/2021

$99M

Acq - Fin

1

5/19/2021

Other

$99M

$39.5M

Acq - Fin - II

2

11/9/2020

$99M

Acq - Fin

1

5/21/2020

Subscribe to see more

$99M

Subscribe to see more

10

1/20/2020

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/8/2021

5/19/2021

11/9/2020

5/21/2020

1/20/2020

Investment Stage

Other

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$39.5M

Note

Acq - Fin

Acq - Fin - II

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

1

2

1

10

10

Omnes Capital Fund History

52 Fund Histories

Omnes Capital has 52 funds, including Omnes Capenergie IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/28/2021

Omnes Capenergie IV

$787.82M

1

1/24/2020

Omnes Croissance 4

Buyouts & Acquisitions

Closed

$419.06M

2

12/20/2018

Omnes Expansion III

Buyouts & Acquisitions

Open

$81.5M

1

9/11/2018

Construction Energie Plus Fund

Subscribe to see more

Subscribe to see more

$99M

10

6/14/2018

Small Cap Fund 3

$99M

10

Closing Date

6/28/2021

1/24/2020

12/20/2018

9/11/2018

6/14/2018

Fund

Omnes Capenergie IV

Omnes Croissance 4

Omnes Expansion III

Construction Energie Plus Fund

Small Cap Fund 3

Fund Type

Buyouts & Acquisitions

Buyouts & Acquisitions

Subscribe to see more

Status

Closed

Open

Subscribe to see more

Amount

$787.82M

$419.06M

$81.5M

$99M

$99M

Sources

1

2

1

10

10

Omnes Capital Partners & Customers

1 Partners and customers

Omnes Capital has 1 strategic partners and customers. Omnes Capital recently partnered with MEDEF on February 2, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

2/27/2018

Client

France

MEDEF selects Omnes as MAI partner

These training sessions will be provided in partnership with BNP Paribas , BPCE , EY and Mazars .

1

Date

2/27/2018

Type

Client

Business Partner

Country

France

News Snippet

MEDEF selects Omnes as MAI partner

These training sessions will be provided in partnership with BNP Paribas , BPCE , EY and Mazars .

Sources

1

Omnes Capital Team

16 Team Members

Omnes Capital has 16 team members, including current Managing Partner, Michel de Lempdes.

Name

Work History

Title

Status

Michel de Lempdes

Managing Partner

Current

Renaud Poulard

Seventure Partners, Safran, and CEA

General Partner

Current

Stephane Monmousseau

Chief Executive Officer

Former

Michel Laversanne

Chief Operating Officer

Former

Antoine Leprince-Ringuet

Managing Partner

Former

Name

Michel de Lempdes

Renaud Poulard

Stephane Monmousseau

Michel Laversanne

Antoine Leprince-Ringuet

Work History

Seventure Partners, Safran, and CEA

Title

Managing Partner

General Partner

Chief Executive Officer

Chief Operating Officer

Managing Partner

Status

Current

Current

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.